Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Genes, Chromosomes and Cancer

• Publication date

  2012-06-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/gcc.21975PMID 22674490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA

  2011influential reference
• Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

  2011influential reference
• Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

  2009cited by this paper
• Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.

  2009influential reference
• The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

  2009cited by this paper
• Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

  2009influential reference
• Structural and numerical variation of FLT3/ITD in pediatric AML.

  2008cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008influential reference
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.

  2006cited by this paper
• Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

  2006cited by this paper
• The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

  2006influential reference
• FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia

  2004cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002influential reference
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002influential reference
• Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

  2002cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper

• Determination of FLT3 mutations and minimal residual deasease monitoring in FLT3-positive acute myeloid leukemia

  2025cites this paper
• Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia

  2025cites this paper
• Targeting USP14/UCHL5: A Breakthrough Approach to Overcoming Treatment-Resistant FLT3-ITD-Positive AML

  2024cites this paper
• CLONAL DYNAMICS AND RELAPSE RISK REVEALED BY HIGH SENSITIVITY FLT3-ITD DETECTION IN ACUTE MYELOID LEUKEMIA.

  2024cites this paper
• FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia

  2024cites this paper
• A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.

  2024cites this paper
• Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

  2024cites this paper
• The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases

  2024cites this paper
• Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing

  2023cites this paper
• The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases

  2023cites this paper
• The FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in AML patients with FLT3-ITD after allo-HSCT: a retrospective propensity-score matching study.

  2023cites this paper
• FLT3 targeting in the modern era: from clonal selection to combination therapies

  2023cites this paper
• Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia

  2023cites this paper
• How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia

  2023influential citation
• How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

  2023cites this paper
• Subclinical minute FLT3‐ITD clone can be detected in clinically FLT3‐ITD‐negative acute myeloid leukaemia at diagnosis

  2023cites this paper
• Set Protein Is Involved in FLT3 Membrane Trafficking

  2023cites this paper
• FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

  2022cites this paper
• Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML

  2022cites this paper
• Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

  2022cites this paper
• Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

  2022cites this paper
• Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype

  2022cites this paper
• Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD

  2022cites this paper
• Comparison of fragment analysis and PCR electrophoresis methods for the detection of FLT3‑ITD mutations in patients with acute myeloid leukemia

  2022cites this paper
• Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

  2022cites this paper
• Genetic basis of acute myeloid leukemia (AML): The most common molecular changes in patients with normal karyotype

  2022cites this paper
• Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study

  2022cites this paper
• Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients

  2022cites this paper
• Whole exome sequencing of pediatric leukemia reveals a novel InDel within FLT-3 gene in AML patient from Mizo tribal population, Northeast India

  2022cites this paper
• FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.

  2021cites this paper
• Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance

  2021cites this paper
• Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia

  2021cites this paper
• Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

  2021cites this paper
• Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations.

  2021cites this paper
• Whole genome, exon mutation and transcriptomic profiling of acute myeloid leukemia: A case report

  2021cites this paper
• FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis

  2021cites this paper
• FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation

  2021cites this paper
• Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

  2020cites this paper
• FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies

  2020cites this paper
• Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms

  2020cites this paper
• Molecular Diagnosis of FLT3 Mutations in Acute Myeloid Leukemia Patients

  2020cites this paper
• Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

  2020cites this paper
• FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.

  2019cites this paper
• Terminal Deoxynucleotidyl Transferase Promotes Acute Myeloid Leukemia By Priming FLT3-ITD Replication Slippage.

  2019cites this paper
• FLT3 inhibitor quizartinib (AC220)

  2019cites this paper
• Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

  2019cites this paper
• Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD–Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway

  2018cites this paper
• Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation

  2018cites this paper
• Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia

  2018cites this paper
• Clinical implications of molecular markers in acute myeloid leukemia

  2018cites this paper
• 异基因造血干细胞移植治疗成人FLT3-ITD阳性急性髓系白血病40例远期疗效分析

  2018cites this paper
• Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199

  2017cites this paper
• Microenvironnement médullaire et résistance des LAM FLT3-ITD aux inhibiteurs de tyrosine kinase : Rôle pivot du récepteur TAM AXL

  2017cites this paper
• Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

  2017cites this paper
• Genetic, Hematologic and Psychological Aspects of Leukemia

  2017cites this paper
• Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia

  2017cites this paper
• Haematological Malignancies Targeting the FLT 3 Mutation in Acute Myeloid Leukaemia

  2017cites this paper
• Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Qualitative and quantitative analysis of molecular markers as a tool for classification, risk assessment and monitoring of acute myeloid leukemia

  2017cites this paper
• FLT3–ITD and its current role in acute myeloid leukaemia

  2017cites this paper
• FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

  2017influential citation
• FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway

  2017cites this paper
• The role of FLT3 inhibitors in the treatment of FLT3‐mutated acute myeloid leukemia

  2017cites this paper
• Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation.

  2016cites this paper
• Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

  2016cites this paper
• Detection the Frequency and Characteristics of FLT3 Internal Tandem Duplication Mutations by Capillary Electrophoresis Assay and Next-Generation Sequencing in.

  2016cites this paper
• ‘Acute myeloid leukemia: a comprehensive review and 2016 update'

  2016cites this paper
• Molecular landscape in acute myeloid leukemia: where do we stand in 2016

  2016cites this paper
• Molecular Genetic Markers in Acute Myeloid Leukemia

  2015influential citation
• Mutational profiling in patients with MDS: ready for every-day use in the clinic?

  2015cites this paper
• Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.

  2015cites this paper
• FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia

  2015cites this paper
• A role of FLT 3 gene mutation in acute myeloid leukemia patients from Pakistan

  2015cites this paper
• Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3‐ITD to detect patients with prognostically adverse AML

  2014cites this paper
• Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

  2014cites this paper
• FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

  2014cites this paper
• Genetic prognostic factors in acute myeloid leukemia

  2014cites this paper
• Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort

  2014cites this paper
• FLT3 Inhibitors in AML: Are We There Yet?

  2014cites this paper
• Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing

  2014cites this paper
• The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

  2014cites this paper
• Mutation position within evolutionary subclonal architecture in AML.

  2014cites this paper
• Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies

  2013cites this paper
• 뀀Ƞ THE FLT3 TYROSINE KINASE IN LEUKEMIA

  2013cites this paper
• Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD

  2013cites this paper
• DNMT3A mutations in AML: a new prognostic factor?

  2013cites this paper
• Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

  2013cites this paper
• The FLT3 Tyrosine Kinase in Leukemia : Deciphering the Downstream Signaling Events and Drug-Escape Mechanisms

  2013cites this paper
• FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance

  2013cites this paper
• Robustness of amplicon deep sequencing underlines its utility in clinical applications.

  2013cites this paper
• Efficacy and resistance of molecularly targeted therapy for myeloid malignancies FLT 3 inhibitors for acute myeloid leukemia : a review of their efficacy and mechanisms of resistance

  2013cites this paper
• Detecting and characterizing fusions and tandem duplications in acute myeloid leukemia transcriptome assemblies using Barnacle

  2012cites this paper